Enanta Pharmaceuticals (ENTA) Other financing activities (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Other financing activities of $69.8 million for Q1 2026, up 49408.51% on a QoQ basis from $141000.0 in Q4 2025, and up 74362.77% year-over-year from N/an in Q1 2025.
Enanta Pharmaceuticals (ENTA) Other financing activities (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Other financing activities history runs 15 years deep, the most recent figure standing at $69.8 million for Q1 2026.
- Quarterly Other financing activities rose 74362.77% year-over-year to $69.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.9 million (up 137252.94% YoY) and the FY2023 annual result came in at $200.0 million, changed N/A from the prior year.
- Other financing activities was $69.8 million for Q1 2026 at Enanta Pharmaceuticals, up from $141000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $198.0 million in Q2 2023 and bottomed at -$18.3 million in Q3 2022.
- A 5-year average of $17.3 million and a median of $94000.0 in 2024 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2022 — Other financing activities tumbled 2043.9% — and 2026, when it soared 74362.77%.
- Enanta Pharmaceuticals' Other financing activities stood at $1.1 million in 2022, then soared by 17483.66% to $198.0 million in 2023, then slumped by 99.95% to $94000.0 in 2024, then soared by 50.0% to $141000.0 in 2025, then soared by 49408.51% to $69.8 million in 2026.
- Business Quant data shows ENTA's Other financing activities at $69.8 million in Q1 2026, $141000.0 in Q4 2025, and -$94000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.81 Mn |
| Mar 31, 2026 | 69.81 Mn |
| Dec 31, 2025 | 141,000.00 |
| Dec 31, 2025 | 141,000.00 |
| Sep 30, 2025 | -94,000.00 |
| Sep 30, 2025 | -94,000.00 |
| Jun 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 94,000.00 |
| Mar 31, 2025 | -94,000.00 |
| Mar 31, 2025 | -94,000.00 |
| Dec 31, 2024 | 94,000.00 |
| Dec 31, 2024 | 94,000.00 |
| Sep 30, 2024 | -79,000.00 |
| Sep 30, 2024 | -79,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 51,000.00 |
| Mar 31, 2024 | 51,000.00 |
| Jun 30, 2023 | 197.99 Mn |
| Jun 30, 2023 | 197.99 Mn |